Literature DB >> 24682505

Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption.

F L Wright1, R J Rodgers.   

Abstract

RATIONALE: The glucagon-like peptide 1 receptor (GLP-1R) agonist exendin-4 potently suppresses food intake in animals and humans. However, little is known about the behavioural specificity of this effect either when administered alone or when co-administered with another anorectic agent.
OBJECTIVES: The present study characterises the effects of exendin-4, both alone and in combination with naltrexone, on behaviours displayed by male rats during tests with palatable mash.
METHODS: Experiment 1 examined the dose-response effects of exendin-4 (0.025-2.5 μg/kg, IP), while experiment 2 profiled the effects of low-dose combinations of the peptide (0.025 and 0.25 μg/kg) and naltrexone (0.1 mg/kg).
RESULTS: In experiment 1, exendin-4 dose dependently suppressed food intake as well as the frequency and rate of eating. However, these effects were accompanied by dose-dependent reductions in all active behaviours and, at 2.5 μg/kg, a large increase in resting and disruption of the behavioural satiety sequence (BSS). In experiment 2, while exendin-4 (0.25 μg/kg) and naltrexone each produced a significant reduction in intake and feeding behaviour (plus an acceleration in the BSS), co-treatment failed to produce stronger effects than those seen in response to either compound alone.
CONCLUSION: Similarities between the behavioural signature of exendin-4 and that previously reported for the emetic agent lithium chloride would suggest that exendin-4 anorexia is related to the aversive effects of the peptide. Furthermore, as low-dose combinations of the peptide with naltrexone failed to produce an additive/synergistic anorectic effect, this particular co-treatment strategy would not appear to have therapeutic significance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24682505     DOI: 10.1007/s00213-014-3507-4

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  101 in total

Review 1.  Animal models to explore the effects of CNS drugs on food intake and energy expenditure.

Authors:  Steven P Vickers; Peter G Clifton
Journal:  Neuropharmacology       Date:  2012-04-10       Impact factor: 5.250

Review 2.  Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake.

Authors:  J C Halford; S C Wanninayake; J E Blundell
Journal:  Pharmacol Biochem Behav       Date:  1998-10       Impact factor: 3.533

3.  Satiety enhancement by selective orexin-1 receptor antagonist SB-334867: influence of test context and profile comparison with CCK-8S.

Authors:  Y Ishii; J E Blundell; J C G Halford; N Upton; R Porter; A Johns; R J Rodgers
Journal:  Behav Brain Res       Date:  2004-12-18       Impact factor: 3.332

4.  Combined stimulation of glucagon-like peptide-1 receptor and inhibition of cannabinoid CB1 receptor act synergistically to reduce food intake and body weight in the rat.

Authors:  E Bojanowska; E Radziszewska
Journal:  J Physiol Pharmacol       Date:  2011-08       Impact factor: 3.011

5.  Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.

Authors:  M Tang-Christensen; P J Larsen; R Göke; A Fink-Jensen; D S Jessop; M Møller; S P Sheikh
Journal:  Am J Physiol       Date:  1996-10

6.  Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.

Authors:  Matthew R Hayes; Scott E Kanoski; Amber L Alhadeff; Harvey J Grill
Journal:  Obesity (Silver Spring)       Date:  2011-03-17       Impact factor: 5.002

7.  Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

Authors:  P J Larsen; C Fledelius; L B Knudsen; M Tang-Christensen
Journal:  Diabetes       Date:  2001-11       Impact factor: 9.461

8.  Rational design of a combination medication for the treatment of obesity.

Authors:  Frank L Greenway; M J Whitehouse; Maria Guttadauria; James W Anderson; Richard L Atkinson; Ken Fujioka; Kishore M Gadde; Alok K Gupta; Patrick O'Neil; Donald Schumacher; Diane Smith; Eduardo Dunayevich; Gary D Tollefson; Eckard Weber; Michael A Cowley
Journal:  Obesity (Silver Spring)       Date:  2008-11-06       Impact factor: 5.002

9.  Exendin-4, a GLP-1 receptor agonist, interacts with proteins and their products of digestion to suppress food intake in rats.

Authors:  Alfred Aziz; G Harvey Anderson
Journal:  J Nutr       Date:  2003-07       Impact factor: 4.798

10.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Authors:  T J Kieffer; C H McIntosh; R A Pederson
Journal:  Endocrinology       Date:  1995-08       Impact factor: 4.736

View more
  2 in total

1.  Targeting GLP-1 receptor trafficking to improve agonist efficacy.

Authors:  Ben Jones; Teresa Buenaventura; Nisha Kanda; Pauline Chabosseau; Bryn M Owen; Rebecca Scott; Robert Goldin; Napat Angkathunyakul; Ivan R Corrêa; Domenico Bosco; Paul R Johnson; Lorenzo Piemonti; Piero Marchetti; A M James Shapiro; Blake J Cochran; Aylin C Hanyaloglu; Asuka Inoue; Tricia Tan; Guy A Rutter; Alejandra Tomas; Stephen R Bloom
Journal:  Nat Commun       Date:  2018-04-23       Impact factor: 14.919

2.  Central and peripheral GLP-1 systems independently suppress eating.

Authors:  Daniel I Brierley; Marie K Holt; Arashdeep Singh; Alan de Araujo; Molly McDougle; Macarena Vergara; Majd H Afaghani; Shin Jae Lee; Karen Scott; Calyn Maske; Wolfgang Langhans; Eric Krause; Annette de Kloet; Fiona M Gribble; Frank Reimann; Linda Rinaman; Guillaume de Lartigue; Stefan Trapp
Journal:  Nat Metab       Date:  2021-02-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.